

January 2022

DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION

Phoxilium 1.2mmol/I phosphate Solutions for haemodialysis/haemofiltration: supply of non-UK labelled batches during the Covid-19 Pandemic

Dear Healthcare Professional,

Summary:

To ensure continuity in supply, Baxter Healthcare Limited has obtained approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to supply multi-lingual packs intended for the French market.

Product Name and MA Number	Active ingredients	UK Product Code	Replacement Product Code	Labelling Language	Batch Numbers
Phoxilium 1.2mmol/l phosphate PL00116/0708	Calcium chloride dihydrate, magnesium chloride hexahydrate, sodium chloride, potassium chloride, sodium hydrogen carbonate, disodium phosphate	113637	113638	French, German and Dutch	21J2810 21J2811 21J2812

Please ensure all relevant staff are made aware of the content of this letter and that the information is communicated to patients.

Please note the following:

- The replacement products are identical to product you will have already been using. The bags are fully compatible with the continuous renal replacement therapy (CRRT) systems on which you currently use Phoxilium.
- The only difference is the languages of the product information. A comparison
 of the labelling is provided as an annex to this letter. The labels have key
 similarities to those of the UK approved product:
 - The product name is the same "Phoxilium".
 - The ink colour used to identify the product on the primary and carton labels is the same green as UK Phoxilium
 - The labelling format for presentation of ingredients amounts, chemical formula etc.



Please ensure the UK Summary of Product Characteristics and package leaflet for Phoxilium are followed. Both documents can be found on the Electronic Medicines Compendium at the following link: www.medicines.org.uk/emc/product/2140

Alternatively, copies of the Summary of Product Characteristics and package leaflet can be obtained from Baxter Medical Information, details below. Copies of the UK labelling can also be provided.

Do you need to do anything different when it comes to placing an order?

No, you order as you always would, using the <u>normal product code</u>. The substitution will be done behind-the-scenes by Baxter Customer Services, once we receive your order. You just need to make sure you communicate amongst your staff, so that they aware that the product code they receive on the ICU, may be different to what they normally expect.

You will be charged the same as for your normal product code.

Call for reporting

Healthcare professionals are asked to report suspected adverse reactions to the Yellow Card Scheme electronically. Report via the website https://yellowcard.mhra.gov.uk/, the free Yellow Card app available from the Apple App Store or Google Play Store, and some clinical IT systems (EMIS, SystmOne, Vision, MiDatabank) for healthcare professionals. Suspected side effects can also be reported by calling 0800 731 6789 for free.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset timing, treatment dates, and product brand name.

Adverse Events relating to Baxter products can also be reported direct to Baxter Pharmacovigilance on 01635 206360, or by email to vigilanceuk@baxter.com.

Any drug product quality complaints (including suspected defective medicines) relating to Baxter products can be reported directly to the Baxter Country Quality Assurance Team on 01604 704603, or by email to UK SHS QA Complaints@baxter.com.

Company contact point

If you have any questions about this letter or require more information about Phoxilium, please contact Baxter Medical Information on 01635 206345 or email medinfo uki@baxter.com.

Yours faithfully

Andrew Warburton Business Unit Head - Acute Therapies

Mosbuts

Baxter UK and Ireland



Comparison Table of product labelling - UK vs replacement product

UK Phoxilium Product code 113637

Phoxilium FR/NL/DE language Product code 113638

UK/ IE/ MT Read the package leaflet before use. Sterite and free from bacterial endotoxins. Before use and learning the form bacterial endotoxins. Before and the properties of the endotoxins bacterians. Verticar fugiss. Esteril jibre de endotoxins bacterians. Solutions is caused to endotoxins bacterians. Comprehe she have greated to endotoxins bacterians. practically free from particles. For single use only.
Discard any unused solution immediately after use. Not for direct infusion: mix both compartments before use. Mix additives before connecting this bag to the extracorporeal circuit. Keep out of the sight and reach of children. Batch No: see "LOT". Expiry date: see "EXP". Read the package leaflet for shelf life of reconstituted product. Store between +4°C +30°C. Do not refrigerate or freeze. UK: PL 00116/0708 IF • PA 2299/053/001

particulas visiveis. Para utilização única. Rejeitar qualquer solução não utilizada imediatamente após utilização. Não utilizar em perfusão direta: mistural ambos os compartimentos antes de usar. Mistural os aditivos antes de ligar este saco ao circuito extracorporal. Manter fora da viata e do alcance das crianças. Nº de lote: ver "LOT". Prazo de validade: ver "EXP". Consultar o folheto informativo quanto ao prazo de validade do produto reconstituido ar entre +4°C e +30°C. Não refrigerar ou congelar. Medicamento sujetto a recelta médica restrita. 5192653

está fransparente v no se observa prácticamente linguna partícula. Para un solo uso. Deseche toda solución que no se haya utilizado inmediatamente después de terminado su uso. No utilizar para infusión directa. Antes de usar, mezciar ambos compartimentos. Mezciar los aditivos antes de conectar esta boisa al circuito extracorpóreo. Mantener fuera de la vista y del alcance de los niños. No. Lote: ver "LOT". Fecha de caducidad: ver "EXP". Para conocer el período de validez del producto una vez reconstituído, leer el prospecto. Conservar a una temperatura entre 4°C y 30°C. No refrigerar o congelar. MEDICAMENTO SUJETO A
PRESCRIPCIÓN MÉDICA.

C.N 664998.5 OH

1.2 HPO 1.2 mmol/l Phosphate | Fosfato | Fosfato



Solution for haemodialysis/haemofiltration | Solução para hemodiálise ou hemofiltração

For intravenous use and/or haemodialysis | Para uso intravenoso e/ou hemodiálise Para uso intravenoso y/o hemodiálisis



Each 1000 ml contains Cada 1000 ml contem Cada 1000ml contiene:					
Before reconstitution Antes da reconstituição Antes de la reconstitución	Α	В			
Calcium chioride Cioreto de cálcio Cioruro de calcio, 2 H ₂ O	3.68 g				
Magnesium chloride Cloreto de magnésio Cloruro de magnesio, 6 H ₂ O	2.44 g				
Sodium chioride Cloreto de sódio Cloruro de sodio		6.44 g			
Potassium chloride Cloreto de potássio Cloruro de potasio		0.314 g			
Sodium hydrogen carbonate Bicarbonato de sódio Bicarbonato de sodio		2.92 g			
Disodium phosphate Fosfato dissódico Fosfato disódico, 2 H ₂ O		0.225 g			
Other Ingredients Outros componentes Otros componentes:					

Small compartment | Countries to purpose the properties |
Small compartment | Compartment pergence | Compartment | carbono (para ajuste de pH)

After reconstitution | Após a reconstituição | Después de la reconstitución, A + B 140

1.25 115.9 mmol/I

Marketing authorisation holder | Titular da autorização de introdução no mercado | Titular: IE/MTPT/ES: Baxier Holding B.V., Kobaliwey 49, 3542 CE Utrecht, Netheriands I Holanda UK: Baxier Healthcare Ltd, Caxton Way, The

ES: Representante Local Autorizado: Baxter, S.L., Poligono Industrial sector 14, C/ Pouet de Camillo nº2, 46394 Ribarroja del Turla, Valencia, España

Baxter

5000 ml Product No.: 113637

FRILUIBE Lire la notice avant utilisation. Stérile et exempte d'endotoxines bactériennes. Vérifier l'intégrité de 'emballage avant utilisation. N'utiliser que si la l'emballage avant unisation. N'uniser que si la solution est limpide et exempte de particules. A usage unique. Les quantités de solution non utilisées doivent être jetées immédiatement après empioi. Ne pas injecter directement: melanger les deux compartiments avant utilisation. Melanger les additifs avant de connecter cette poche au circuit extracorporel. Tenir hors de la vue et de la portée des enfants. Lire la notice concernant la durée de conservation de la solution reconstituée. No. de lot: voir "lot". A utiliser avant: voir "exp". Conserver entre +4°C et +30°C. Ne pas mettre au réfrigérateur. Ne pas congeler. FR: Médicament soumls à prescription hospitalière. Médicament autorisé n°.: 34009 394

Exploitant: BAXTER SAS, Immeuble Berlioz, 4 bis rue de la Redoute. 78280 Guvancourt. FRANCE BE: Médicament soumis à prescription médicale BE340916 LU: 2009050022/0517084

BELAT Packungsbellage beachten. Sterli und frei von bakteriellen Endotoxinen. Vor der Anwendung auf Undichtigkeiten überprüfen. Nur klare und partikeifreie Lösungen verwenden. Nur zum einmaligen Gebrauch.

Restlösung umgehend nach Gebrauch verwerfen. Nicht zur direkten Infusion: Vor der Anwendung die helden Kammern mischen. Zusäfze vor dem Anschließen dieses Beutels an den extrakorporalen Kreislauf zumischen. Arzneimittel okuskopor alan i Helsala i Zumbewahren. Bezüglich der Verwendbarkeit der gebrauchsfertigen Lösung beachten Sie bitte die Packungsbellage. Ch. -B.: siehe 10f. Verwendbar bis: siehe *exp*. Phoxillum zwischen +4°C und +30°C lagern. Nicht im Kühlschrank lagern

AT: Rezept- und apothekenpflichtig Z. Nr. 1-28490 BE: Verschreibungspflichtig BE340916

NLIBE Lees voor het gebruik de bijsluiter. Steriel en vrij van bacterlêle endotoxinen. Voor gebruik op lekken controleren. Niet gebruiken tenzij de oplossing helde is en er nagenoeg geen zwevende deeltjes te zien zijn. Uitsluitend voor eenmalig gebruik. Niet gebruikte vloelstof dient te worden weggegoold. Niet voor directe infusie: Voor gebruik de Inhoud van beide compartimenten mengen. Meng toevoegingen vooraleer de zak wordt verbonden met het extracorporele circuit. Bulten het zicht en bereik van kinderen houden. Lees de bijsluiter voor de houdbaarheid van het samengevoegde product. Lotnummer: zie "lot". Ulterste gebruiksdatum: zie "exp". Bewaren tussen +4°C en +30°C. Niet in de koelkast of de vriezer bewaren NL: U.R. RVG 101928
BE: Geneesmiddel op medisch voorschrift.

BE3/0910





Solution pour hémodialyse/hémofiltration | Hämodialyse-/Hämofiltrationslösung | Oplossing voor hemodialyse/hemofiltratie

Voie intraveineuse et/ou hémodialyse | Intravenöse Anwendung und/oder Hämodialyse | Voor intraveneuze toediening en/of hemodialyse.

5000 ml



Formula pour 1000 mil 1000 mil cosung anthanen cika 1000 mil bavat.		
Avant reconstitution Vor der Mischung Voor samenvoegen		В
Chiorure de calcium Calciumchiorid Calciumchioride, 2 H ₂ O	3,68 g	
Chiorure de magnésium Magnesiumchiorid Magnesiumchioride, 6 H ₂ O	2,44 g	
Chlorure de sodium Natriumchlorid Natriumchloride		6,44 g
Chiorure de potassium Kallumchiorid Kallumchioride		0,314 g
Bicarbonate de sodium Natriumhydrogencarbonat Natriumbicarbonaat		2,92 g
Phosphate disodique Natriummonohydrogenphosphat (Ph. Eur.) Dinatriumfosfaat, 2 H ₂ O		0,225 g
Autres composants Sonstige Bestandtelle Andere stoffen:		

Petit compartiment A I Kleine Kammer A I Ult het kleine Grand compartment B | Große Kammer B | Uit het grote compartiment A: Eau pour preparations injectables, a chiorhydrique (pour ajustement du pH) | Wasser für inje Saizsaure (zur Anpassung des pH-Werts) | compartiment B: Eau pour préparations injectables, dioxyde de arbone (pour ajustement du pH) | Wasser für injektionszwecke, cohiendioxid (zur Anpassung des pH-Werts) | Water voor injecties, Water voor injecties, zoutzuur (voor pH-aanpassing poistofdioxide (voor pH-aanpassing).

115,9 Osmolarité théorique | Theoretische Osmolarität | Berekende osmolaritelt: 293 mOsm/

Titulaire | Pharmazeutischer Unternehmer | Farmaceutische vergunninghouder Baxter Holding B.V., Kobaltweg 49, 3542CE Utrecht, Niederlande | Nederland | Pays-Bas

Après reconstitution | Nach der Zubereitung | Na samenvoegen, A + B

RESPECTER LES DOSES PRESCRITES

Liste I - Uniquement sur ordonnance

Baxter

Product No.: 113638

ᇤ Label Ø



